2-isopropyl-3-methyl-butyric acid-((S)-1-methyl-heptyl ester) | 101443-43-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-isopropyl-3-methyl-butyric acid-((S)-1-methyl-heptyl ester)
• 英文别名: 2-isopropyl-3-methyl-butyric acid-((S)-1-methyl-heptyl ester)；2-Isopropyl-3-methyl-buttersaeure-((S)-1-methyl-heptylester)
• CAS: 101443-43-0
• 化学式: C₁₆H₃₂O₂
• 分子量: 256.429
• InChiKey: BKDUUEIMXQVCNS-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.82
• 重原子数：
  18.0
• 可旋转键数：
  9.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  26.3
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为产物：
  描述：

  3-甲基-2-丙-2-基丁酸 在 氯化亚砜 作用下， 生成 2-isopropyl-3-methyl-butyric acid-((S)-1-methyl-heptyl ester)
  参考文献：
  名称：

  Exercise-induced microalbuminuria in patients with active acromegaly: Acute effects of slow-release lanreotide, a long-acting somatostatin analog

  摘要：

  Recent clinical studies have demonstrated an increase of urinary albumin excretion (UAE) at rest in acromegalic patients and, on the other hand, a reduced UAE in patients with growth hormone (GH) deficiency. Physical exercise is known to induce abnormal UAE in patients with diabetes, probably unmasking early glomerular alterations. The effect of exercise on UAE in acromegaly is not known. Moreover, the effect of acute but sustained GH inhibition in acromegaly on UAE at rest and after exercise has never been studied. The aim of our study was to evaluate the acute short-term effects of slow-release lanreotide (SR-L), a long-acting somatostatin analog, on UAE and alpha 1-microglobulinuria (A-1-M), a marker of renal tubular damage, at rest and after exercise in 7 normotensive patients with active acromegaly and normal renal function (4 males and 3 females; mean age, 53 +/- 3.1 years; body mass index [BMI], 27.3 +/- 1.1 kg/m(2)) at baseline and 7 and 14 days after SR-L injection (30 mg). Two of the acromegalic patients were microalbuminuric at rest, and in other 3 cases, UAE was in the borderline range (10 to 20 mu g/min). At baseline in the acromegalic subjects, we found a significant increase in UAE at rest with respect to 7 normal subjects considered as a control group. GH and insulin-like growth factor-1 (IGF-1) were also reduced compared with baseline 7 and 14 days after SR-L injection (GH, 13.4 +/- 7.3 and 13.61 +/- 7 v 18.5 +/- 9.3 mu g/L, P < .05; IGF-1, 230 +/- 53 and 255 +/- 54 v 275 +/- 64 mu g/L). Concomitantly, we observed a significant decrease of UAE at rest and after exercise and 7 and 14 days after SR-L injection as compared with baseline values (27.3 +/- 20.5 and 18.2 +/- 13.7 v 35.3 +/- 12.8 mu g/min, P < .05; exercise, 48.5 +/- 24.1 and 18.6 +/- 6.8 v 68.3 +/- 39.7 mu g/min, P < .05). A-1-M always remained in the normal range (<12 mg/L) both at rest and after exercise. We can thus conclude that in acromegaly, submaximal exercise induces abnormal increases in microalbuminuria. We hypothesize that this phenomenon may be due to the functional glomeruler involvement. SR-L can significantly reduce UAE at rest and after exercise in the short-term in acromegaly, probably via a decrease in circulating GH levels. Copyright (C) 2000 by W.B. Saunders Company.

  DOI：

  10.1016/s0026-0495(00)80040-2